Hydrogen peroxide (H 2 O 2 ) and methyl mercury induced the liberation of arachidonate and its metabolites from human washed platelets. [ 14 C]Eicosanoids were extracted from the supernatants of [ 14 C]arachidonate-prelabelled platelets and analysed by thin layer chromatography and radioscanning. Thromboxane B 2 (TXB 2 ), 12(S)-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) were found s stabie metabolites, together with unreacted arachidonate. In the presence of dazoxiben, a shift in eicosanoid metabolism was observed towards prostaglandin E 2 (PGE 2 ), prostaglandin D 2 (PGD 2 ) and prostglandin F 2a (PGF^), while in the presence of indomethacin there was a shift towards 12-HETE and unmetabolized arachidonate. The concentration pattern of those metabolites resembled that found with the physiological agonist, thrombin. H 2 O 2 and methyl mercury also induced platelet shape change, aggregation and secretion. The EC 50 values for the induction of shape change and aggregation were 27 and 850 μπιοΐ/ΐ for H 2 O 2 and 0.33 and 2.7 μιηοΐ/ΐ for methyl mercury, respectively. The [ 3 H]serotonin release required higher Stimulus concentrations and amounted to 45% with 2 μηιοΐ/l H 2 O 2 and to 16% with 3 μιηοΐ/ΐ methyl mercury. These effects on platelet function were absent in platelets exposed to acetylsalicylic acid and prevented by indomethacin, the prostaglandin Ha (PGH 2 )/thromboxane A 2 (TXA 2 ) receptor antagonist, daltroban, and the functional antagonist, iloprost. In contrast, none of these drugs suppressed the formation of ( 14 C]eicosanoids, indicating that the platelet activation by H 2 O 2 and methyl mercury essentially requires previous PGH2/TXA 2 formation. As expected, the thromboxane synthase inhibitor, dazoxiben, did not prevent, but instead potentiated the activation by H 2 O 2 and methyl mercury through accumulated PGH 2 . These results show that H 2 O 2 and methyl mercury selectively trigger the mobilization of endogenous arachidonate. In platelets exposed to acetylsalicylic acid or in the presence of a PGH 2 /TXA 2 receptor antagonist, they are model Stimuli for investigating endogenous eicosanoid formation without the interference of a receptor^operated activation cascade. Therefore, H 2 O 2 and methyl mercury are valuable tools for elucidating the unresolved trigger meehanisms of eicosanoid release and for studying approaches to its selective Inhibition. 
of platelet activation (3 -5) . Acetylsalicylic acid (asThe synthesis f eicosanoids in human platelets is pirin®) and other non-steroidal anti-inflammatory triggered by their physiological agoriists thrombin, drugs reduce platelet activation, because they inhibit Collagen, ADP etc., but it is not essential for platelet --.-activation by these Stimuli (1) EC^ concentration of an agonist that produces 50% eflect; they play a functional role s strong feedback agonists TLC, thin layer chromatography.
PGH 2 and TXA 2 formation from endogenous arachidonate released upon platelet Stimulation by either of the above mentioned agonists. Antagonists acting on the PGH 2 /TXA 2 receptor exert a similar inhibitory effect by preventing PGH 2 and TXA 2 from stimulating their common PGH 2 /TXA 2 receptor (6). However, neither cyclooxygenase inhibitors nor TXA 2 /PGH 2 receptor antagonists suppress the mobilization of arachidonate, which is the key event in eicosanoid formation (7) . Thus, these drugs cannot prevent the mobilization and metabolism of free arachidonate to biologically active products. In particular, cyclooxygenase inhibitors like acetylsalicylic acid may enhance the formation of lipoxygenäse products, such äs 12-HETE 1 ) in platelets (8) and leukotrienes from plateletderived arachidonate in leukocytes (9) . Therefore, there is considerable pharmacological interest in the search for inhibitors of the initiation of eicosanoid release, namely the mobilization of arachidonate.
The biochemical link between the receptor-operated activation cascade and eicosanoid release is still unknown (10, l i), äs are specific inhibitors of the arachidonate release (12) . Several enzymes regulate the free arachidonate concehtration. Phospholipase A 2 ? ) supplies the major portion of free arachidonate by liberation from phospatidylcholine and to a lesser extent from phosphatidylethanolamine (13, 14) . The sequential action of phospholipase C 2 ) and diglyceride and monoglyceride lipases contributes to less than 15 percent of the arachidonate mobilized during platelet Stimulation with thrombin (15) . On the other hand, arachidonyl-CoA synthetase 2 ) (16) and lysophospholipid acyltransferase 2 ) (17) can rapidly Sequester a large amount of free arachidonate· and reincorporate it into the phospholipids by the reacylating pathway (18) . Therefore, the extent to which an activation of the deacylation or an Inhibition of the reacylation pathway contribute to the arachidonate mobilization is the subject of an ongoing debate (19) . The biochemical study of arachidonate release is difficult, because both membrane-bound enzymes and membrane-associated Substrates are involved. Another problem arises from the lack of specific biochemical and pharmacological tools to interfere with the complex mechanism that controls the concentration of free arachidonate. methyl mercury chloride may prove to be such tools, suitable for investigating the underlying mechanism. It is shown in the present work that both agents mobilize arachidonatCj independently of the activation cascade. Thus they act more directly on eicosanoid release than thrombin or other Stimuli, which require the receptor-operated activation cascade.
• r H 2 O 2 belongs to the reactive oxygen species produced by phagocytosing or otherwise stimulated neutrophils. The amount produced by 2.5 · l O 6 neutrophils reaches 6 nmol per 20 minutes (20, 21) . A much less potent source of H 2 O 2 is the platelet stimulated with latex particles or opsoriized zymosan (22) . In studies on the actions of H 2 O 2 on platelets in vitro, different authors report on the one hand an inhibition of platelet aggregation induced by arachidonate (21, 23) and an inactivation of the platelet cyclooxygenase (24) ; and on the other hand, an enhancement by H 2 O 2 öf the effects of a variety of platelet agonists (25) and its role äs a cosubstrate in the activation of the platelet eyclooxygenäse 2 ) (26). Our own work on the role of reactive oxygen species in platelet physiology (27, 28) led us to use H 2 O 2 äs a model Stimulus of platelet activation via thromboxane formation (29) . While H 2 O 2 represents a physiological agent, methyl merĉ ury is formed by microorganisms from inorganic mercury in industrial waste and accumulates in man at the end of the food chain through its solubility in lipids. It causes toxic effects on brain, liver and kidneys (for review see 1. c. (30) ) but its mechanism of action has not yet been clarified. Inhibitory effects of methyl mercury were described ön adenylate cyclase (31, 32) and on 12-lipoxygenase 2 ) (33), leading to a reduced inhibition of thromboxane synthesis by 12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid (l 2-HPETE). Additionally, the whole blood glutathione peroxidase activity and total blood glutathione is decreased by methyl mercury, whereas the serum levels of TXB, 1 ) and PGE^) increase (34) . MacFarlane (23) reported that methyl mercury indüces platelet shape change, aggregation and the release reaction, and that these effects could be suppressed by an inhibition of the cyclooxygenase, The preserit stüdy demonstrates that the target of H 2 O 2 and methyl mercury is the mobilization of endogenous arachidonate. Thus H 2 O 2 and methyl mercury are üsefül model substances for biochemical and pharmacological research on the initial step of eicosanoid release. 
Materials and Methods

Biochemicals
Preparation of washed platelets
Blood was taken only from healthy volunteers, who all disclaimed taking any drugs during the previous week. Disc shaped washed platelets were prepared from whole blood anticoagulated with 1/7 vol ACD NIH-formula A (8 g/l citric acid, 22 g/l sodium citrate, 24.5 g/l hydrous dextrose) according to our method of washing with acid citrate (35) . The platelets were sedimented from platelet-rich plasma by 7 min centrifugation at 330g and resuspended in a solution containing NaCl 120 mmol/1, KC1 5 mmol/1, CaCl 2 2 mmol/1, MgCl 2 l mmol/1, glucose 5 mmol/1, albumin 2 g/l, apyrase 50 mg/1, sodium phosphate/NaOH 30 mmol/1, pH 6.5. When platelets were treated with acetylsalicylic acid 5 mmol/1, a freshly prepared solution of 20 mmol/1 in isotonic TES buffer pH 7.4 was added to the platelet-rich plasma and incubated for 30 min at 22 °C prior to the washing procedure. Where platelet secretion was to be measured, platelet-rich plasma was incubated with 0.08 μηιοΐ/ΐ (« 60 kBq) [ 
Rheooptical measurements of shape change and aggregation
Shape change and aggregation were measured turbidimetrically in a dual channel aggregoirieter (Labor, Ahrensburg, Ί?. R. G.) at 37 °C by the method established by Born (36) with modifications s published earlier (35) . Shape change experiments were performed in the presence of EDTA 2 mmol/1 at a stirring speed of 400 min" 1 . In aggregation experiments, 300 mg/1 of fibrinogen were added and the stirring speed was 1000 min" 1 . Preincubation of platelet suspensions with test substances started 5 minutes prior to Stimulation. The instrumental arrangement for measurements and the quantification of shape change and aggregatipn were described previously (35).
Release of [ 3 H]serotonin
The secretion of pH]sef otonin from platelet dense granules was determined s the decrease of die platelet bound radioactivity (35) . The reuptake of serotonin was inhibited by the presence of imipramine 2 μηιοΐ/ΐ. Aliquots were taken from incubates three minutes after addition of the activating agent and were mixed with 50 μΐ of an 0.1 mmol/1 ice-cold EDTA solution pH 7.4, rapidly cooled to 0 9 C and centrifuged for 30s in an Eppendorf 3200 centrifuge at 0 °C. The radioactivity of 200 μΐ aliquots of the superaat nt was counted in a liquid scintillation counter. were added and after another 5 minutes, platelet Stimuli were applied in a volume of 10 μΐ. The final test volume was l ml. In the controls, test medium was added instead of drugs. After the desired time of incubation, the reaction was stopped by acidifying to pH 3 with 10 μΐ of concentrated formid acid. Samples were centrifuged at 10000g for 15 minutes and the cell-free supernatants extracted twice with ethyl acetate. The combined organic phases were dried under nitrogen, redissolved in 100 μΐ of chloroform/methanol (2 + l, by vol.) and analysed by thin layer chromatography. The overall recovery of the radioactivity in the extracts and the platelet Sediments averaged 86 percent of the platelet-bound radioactivity after prelabelling. 
Release of lactate dehydrogenase
As a parameter of cytoplasmic leakage, lactate dehydrogenase 2 ) was measured in an optical test (Monotest, Boehringer Mannheim, Mannheim, F. R. G.). Aliquots were taken from the incubates five minutes after the addition of H 2 O 2 or methyl mercury, and the supern tants prepared by centrifugation for 30 s in an Eppendorf 3200 centrifuge at 0 °C. The lactate dehydrogenase in the supernatants was compared with the total lactate dehydrogenase released from control platelets after their lysis by three cycles of freezing and thawing.
Statistics
Data are expressed s mean + S. E. M. Statistical coniparisons were performed using Studenfs t-test for paired data. The null hypothesis was rejected if p < 0.05. The concentration effect curves were calculated from data points by multiple iterations using a non-linear sigmoidal leasl squares regression fit algorithm developed by Marqitardt (37) and improved by Tabata & Ito (38) . The algorithm is part of the statistics and plotter graphics Software package GRAPHPAD from ISI (USA). fig. 4a and 4b) , respectively, whereas a f ll shape change remained unaffected. H 2 O 2 was used at concentrations not higher than 2 mmol/1 in functional tests, since at higher concentrations it released small bubbles of molec lar xygen that severely inteffefed with the turbidimetric measurements of shape change and aggregation. The aggregating effect of methyl 
Results
Treatment
. ? 1 10 [mmpl/U 2 and HHT arise from the latter two compounds (41, 42) . The unstable intermediary products, PGH 2 and TXA 2 , cause shape change, aggregation and secretion, which can be suppressed by inhibitors of their formation such s acetylsalicylic acid and indomethacin, or by inhibitors of their action such s the PGH 2 / TXA 2 receptor antagonists, sulotroban (43) and daltroban (44) . The thromboxane synthase inhibitor, dazoxiben, enhances the platelet response (29) due to accumulated PGH 2 , which shares the same receptor s TXA 2 (45) . Acetylsalicylic acid (46) or daltroban reduce but never suppress the platelet responses to thrombin, ADP, platelet activating factor, serotonin or the stable thromboxane mimetic U 46619 (1). In contrast, acetylsalicylic acid, sulotroban and daltroban prevented the platelet Stimulation by H 2 O 2 and methyl mercury. Therefore, platelet Stimulation by H 2 O 2 and methyl mercury essentially requires the formation and action of PGH 2 and TXA 2 , whereas each of the other mentioned agonists also elicits a platelet response independently of PGH 2 and TXA 2 formation. This implicates different mechanisms for triggering eicosanoid forin tion with H 2 O 2 or methyl mercury and with the other physiolpgical agonists.
Thrombin, ADP, platelet activating factor, serotonin and U 46619 act on platelets via specific receptors. Their platelet-activating signal is transmitted by an activation of the ph spholipase C and the formation of inositol-l,4,5-trisphosphate and diacylglycerol, which increase the intracellular free Ca 2+ concentration and ctivate protein kinase C, respectively (47, 48) . These events lead to shape ch ge, aggregation and secretion and can be juahibited by agents that stimulate the cyclic AMP formation, such s prostacyclin (49, 50) , Therefpre, agents capable of stimulating cAMP accumulation can be expected to inhibit the thrombin-induced eicosanoid release, if this release depends on the thrombin-induced activation cascade. In fact, the stable pr stacyclin mimetic, iloprost (51) , and the cyclic AMP phosphodiesterase inhibitor, LU 41.453, inhibited the thrombin-induced eicosanoid release, but did not reduce the mobilization of arachidonate and the formation of eicosanoids caused by methyl mercury. This confirms that eicosanoid release is secondary to platelet activation by thrombin, whereas methyl mercury does not require the activation cascade for its effect on eicosanoid release. The primary effect of H 2 O 2 and methyl mercury on arachidonate mobilization is also demonstrated by the observation that indomethacin does not suppress the eicosanoid release, although it prevents the H 2 O 2 -and methyl mercury-induced shape change, aggregation and serotonin secretion.
A potent Stimulus for eicosanoid release in platelets is an intimate platelet contact (5) , an effect which is most pronounced in citrated plasma (52) . Therefore, if platelets are allowed to aggregate, their aggregation and secretion response is enhanced s a consequence of PGH 2 /TXA 2 fonnation. The aggregation (= contact) can be definitely suppressed by EDTA, which interferes with the binding of the aggregation cofactor, fibrinogen, to its glycoprotein Ilb/IIIa receptors on the platelet surface (53) . Even in the presence of EDTA, H 2 O 2 2 mmol/1 and methyl mercury 3 μιηοΐ/ΐ induced a f ll shape change and a certain release of serotonin. Thus, these agents were potent Stimuli of PGH 2 /TXA 2 formation, even in the absence of an aggregation-induced secondary mobilization of arachidonate.
Higher concentrations than 2 mmol/1 of H 2 O 2 and 3 μπιοΐ/ΐ of methyl mercury were not used for specific stimulations of the eicosanoid release, because of certain side effects. H 2 O 2 (5 -30 mmol/1) still enhanced the eicosanoid release and 12-HETE production, but suppressed the fonnation of TXB 2 and HHT. This is consistent with the Inhibition of the cyclooxygenase observed by Kawaguchi et al. (24) in rabbit platelets. In addition, oxygen bubbles were formed when H 2 O 2 was present at > 1.5 mmol/1, due to the instability of H 2 O 2 at high concentrations. When more than 3 or 20 μηιοΐ/ΐ of methyl mercury were applied to 200 • 10 9 /1 or 2 · 10 12 /1 platelets, respectively, shape change and aggregation occurred, despite the presence of indomethacin. In other words, methyl mercury at these high concentrations elicits another platelet-activating effect that is not mediated by the formation and action of PGH 2 and TXA 2 . Even at the highest concentrations tested, lactate dehydrogenase liberation remained below 3% with 30 mmol/1 H 2 O 2 and 4% with l mmol/1 methyl mercury, showing that cell lysis did not occur to an appreciable degree.
The mechanism whereby H 2 O 2 and methyl mercury selectively trigger the release of arachidonate remains to be elucidated. In platelets, free arachidonate is liberated mainly by ph spholipase A 2 activated by cytoplasrnic Ca 2+ , which increases during platelet ac-tivation (54) . This mechanism is thought to be operative in the thrombin-induced eicosanoid release (55, 56) but is unlikely to be involved in the eicosanoid release induced by H 2 O 2 or methyl mercury. A small rise in cytoplasmic Ca 2+ is sensitively reflected by a spherization of the platelets (57) . In platelets exposed to acetylsalicylic acid however, no shape change is observed upon Stimulation with H 2 O 2 or methyl mercury, despite considerable arachidonate release. Whether H 2 O 2 or methyl mercury exert a direct, Ca 2 +-independent effect on the phospholipase A 2 2 ) activity or interfere with the reacylating pathway of arachidonate is currently under investigation in our laboratory. Both the phospholipase A 2 (58) and the reac-'ylating enzymes, arachidonyl-CoA synthetase 2 ) (16) and lysophospholipid acyltransferase 2 ) (17), have high activities in platelet membranes, which suggests a high turnover rate of arachidonate deacylation and reacylation. Under these conditions, an Inhibition of the reacylating enzymes could just äs well lead to a rise in free arachidonate, äs to an activation of the phospholipase A 2 .. Since in contrast to thrombin and other physiological agonists, H 2 O 2 and methyl mercury have a direct effect on arachidonate release, these agents are valuable tools for investigating the biochemical mechanism of arachidonate mobilization. Irrespective of whether their target(s) is (are) located within the phospholipase A 2 or the reacylation pathway, they provide models which not only pennit the study of the regulation of free afdchidonate in platelets, but also provide an experimental approach to its specific Inhibition. Specific drugs that suppresss arachidonate mobilization by an inhibitory effect on phospholipase A 2 or a stimulating effect on the reacylating enzymes are not yet available. The use of specific Stimuli of arachidonate release, such äs H 2 O 2 and methyl mereury, should facilitate the search for and the characterization of selective inhibitors of arachidonate release.
